预混门冬胰岛素30和预混人胰岛素30R治疗2型糖尿病的对比研究

A comparison of premixed insulin aspart 30 and premixed human insulin 30R in treatment of type 2 diabetes

目的:探讨每日2次注射预混门冬胰岛素30(诺和锐30)和预混人胰岛素30R(诺和灵30R)治疗2型糖尿病患者的疗效和安全性。方法:68例经口服降糖药物控制不佳的2型糖尿病患者被随机分为诺和锐30治疗组和诺和灵30R治疗组,分别采用每日早,晚餐前注射诺和锐30和诺和灵30R,进行为期12周的观察。比较两组患者糖化血红蛋白(HbA1c),7个时点血糖,低血糖发生频率等。结果:诺和锐30治疗组的早,晚餐后血糖明显低于诺和灵30R治疗组(P<0.01);诺和锐30治疗组低血糖发生次数低于诺和灵30R治疗组,但差异无统计学意义(P>0.05),诺和锐30治疗组无严重低血糖发生。结论:对于2型糖尿病患者,每天2次注射诺和锐30较诺和灵30R能更明显地降低餐后血糖及减少低血糖风险,同时更易于为患者接受。

Objective：To compare the safety and efficacy of premixed insulin aspart 30（BIAsp30） with premixed human insulin 30R （BHI30） used in twice-daily injection regimen in patients with type 2 diabetes. Methods：Sixty-eight patients with inadequate glycemia control by oral drug were randomly divided into two groups using twice-daily insulin for 12 weeks comparison of BIAsp30 and BHI30. We compared HbAlc,seven-point blood glucose and frequency of hypoglycemia in two groups. Results：Blood glucose after breakfast and after dinner were significantly lower in BIAsp30 group than in BHI30 group（P〈0.01 ）. The number of hypoglycemic episodes was less in BIAsp30 group than in BHI30 group, but the contrast had no statistical significance（P〉0.05 ）, meanwhile no serious hypoglycemia happened in BIAsp30 group. Conclusion：Post-prandial glycemia control was significantly improved ,without increasing the risk of hypoglycemia, when people with type 2 diabetes were treated in twice-daily injection regimen with BIAsp30, as compared with BHI30.